GlassScriptPhysician profile
Luiz Nascimento
NPI 1245228261
$3,009.46
in general payments reported to CMS, 2019-2025
26 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,366 · 2020: $323 · 2021: $171 · 2023: $203 · 2024: $823 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,136 · Education: $13.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,136.26 |
| Education | $13.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $681.61 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $467.35 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $385.90 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $292.97 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $193.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $142.69 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $111.75 | 2019-2024 | Verquvo |
| Pfizer INC. | $85.23 | 2019-2021 | |
| Akebia Therapeutics INC | $79.03 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $68.01 | 2024 | Voquezna |
| Sanofi-Aventis U.S. LLC | $60.29 | 2019 | |
| Shield Therapeutics INC | $57.94 | 2024-2025 | |
| Astellas Pharma US INC | $55.83 | 2019-2020 | |
| Ani Pharmaceuticals, INC. | $53.89 | 2024 | Purified Cortrophin Gel |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.55 | 2019-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $42.32 | 2019 | |
| Ardelyx, INC. | $26.52 | 2024 | Ibsrela |
| Mallinckrodt Enterprises LLC | $26.29 | 2019 | |
| Dexcom, INC. | $24.28 | 2023 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $22.56 | 2019 | |
| Daiichi Sankyo INC. | $16.55 | 2020 | |
| Mylan Specialty L.P. | $15.49 | 2023 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $14.87 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.98 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.52 | 2023 | Rexulti |
| Amarin Pharma, INC. | $13.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luiz Nascimento listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.